How Benign Are Juvenile Polyps?

A recent retrospective study (N Ibrahimi et al. JPGN 2019; 69: 668-72) reviewed juvenile polyp characteristics over a 14 year period (2003-17) from 213 pediatric subjects who underwent 326 procedures.  The authors state their review was intended for nonsyndromic juvenile polyps, though 23 of the patients had ≥5 polyps (which is incongruous with their presented methods of including children with less than 5 polyps).

Key findings:

  • The authors state that polyp recurrence rates on repeat colonoscopy were 1.5% if one polyp, 19.2% if 2-4 polyps, and 82.6% if 5-10 polyps
  • Juvenile polyps harbored adenomatous changes in 26 (12%) of patients
  • The presence of adenomatous changes did not correlate with polyp number; however, a polyp on the right-sided was more likely to harbor adenomatous changes

It is possible that some of the ‘recurrent’ polyps were missed polyps, as polyps can be easily overlooked.  I had a recent experience of removing numerous polyps (14) from a child recently and some were identified in part due repeated visualization of several colonic segments.  The recent ESPGHAN position paper is useful in children with multiple polyps; their recommendations include: In a child with a single JP, a repeat colonoscopy is not routinely required. (Weak recommendation, very low quality of evidence).

My take: This report is notable for the following:

  1. a fairly high rate of adenomatous changes in juvenile polyps.
  2. a high recurrence rate for children with multiple polyps

Related blog posts:

Quebec City

Disclaimer: This blog, gutsandgrowth, assumes no responsibility for any use or operation of any method, product, instruction, concept or idea contained in the material herein or for any injury or damage to persons or property (whether products liability, negligence or otherwise) resulting from such use or operation. These blog posts are for educational purposes only. Specific dosing of medications (along with potential adverse effects) should be confirmed by prescribing physician.  Because of rapid advances in the medical sciences, the gutsandgrowth blog cautions that independent verification should be made of diagnosis and drug dosages. The reader is solely responsible for the conduct of any suggested test or procedure.  This content is not a substitute for medical advice, diagnosis or treatment provided by a qualified healthcare provider. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a condition.

Colorectal Adenomas

A good review on colorectal adenomas: WB Strum. NEJM 2016; 374: 1065.

A couple of points from review:

  • There has been a wealth of new data in last 10 years.
  • In 2016, ~134,000 persons in U.S. will be found to have colorectal cancer & 49.000 will die from it.
  • Adenomas are present in 20-53% of the U.S. population older than 50 years of age.
  • Adults in the U.S. have a lifetime risk of ~5% of adenocarcinoma.
  • Two major pathways from adenomas to adenocarcinoma: chromosomal instability and micro satellite instability via predominantly ~25 genes.
  • Screening interval recommendations (Table 1): 10 years for no polyps or juvenile polyps in rectum/sigmoid.
  • Aspirin therapy may be beneficial but apply to persons who have no increased risk of bleeding and are willing to take low-dose aspirin (81 mg) daily.  The greatest benefit is expected in persons 50 to 59 years and a potential benefit in 60 to 69 years of age.
  • Diets that are low in fat, regular physical exercise, maintenance of an appropriate body-mass index, and avoidance of smoking are recommended to lower risk.

Related full text article: Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: USPSTF Recommendations Excerpt:

The USPSTF recommends initiating low-dose aspirin use for the primary prevention of CVD and CRC in adults aged 50 to 59 years who have a 10% or greater 10-year CVD risk, are not at increased risk for bleeding, have a life expectancy of at least 10 years, and are willing to take low-dose aspirin daily for at least 10 years. (B recommendation)The decision to initiate low-dose aspirin use for the primary prevention of CVD and CRC in adults aged 60 to 69 years who have a 10% or greater 10-year CVD risk should be an individual one.”

Related blog posts:

Colonic adenoma